Ampyra (dalfampridine) – Seizure Risk for Multiple Sclerosis Patients

BACKGROUND: Ampyra was approved to improve walking in patients with MS. Seizures are a known side effect of Ampyra, and seizure risk increases with higher blood levels of the drug. Ampyra is eliminated from the body through the kidneys, and patients with kidney impairment may develop higher blood levels of the drug, thereby increasing their seizure risk.

via Safety Alerts for Human Medical Products > Ampyra dalfampridine: Drug Safety Communication – Seizure Risk for Multiple Sclerosis Patients.


A nice article on the topic.

The Baseline Scenario

By James Kwak

Usually the New York Times gives reasonably good financial advice—or, at least it avoids giving really bad advice. Today, however, Paul Sullivan’s column borders on the latter. The question is whether to take a pension payout as a lump sum or as an annuity (a guaranteed, fixed amount per year until you die).

Sullivan’s column isn’t all bad. He talks about the importance of being able to manage your money and the need to be comfortable with risk if you take the lump sum. He also points out the annuity (in this case, based on what GM workers are being offered) isn’t indexed to inflation, which is an important consideration. And he doesn’t come down on one side or the other, although he says he would take the lump sum because, he says, “I would rather control the money myself.”

View original post 609 more words

Melanoma on Rise with Indoor Tanning

Overall, there was a 20% increased risk for melanoma with any indoor tanning (RR 1.20, 95% CI 1.08 to 1.34), according to Mathieu Boniol, PhD, of the International Prevention Research Institute in Lyon, France, and colleagues.

But the risk nearly doubled when sunbed use began before age 35 (RR 1.87, 95% CI 1.41 to 2.48), they reported online in BMJ.

via Medical News: Melanoma on Rise with Indoor Tanning – in Oncology/Hematology, Skin Cancer from MedPage Today.